It has been similarly reported that the recurrence risk is highest amongst women suffering from triple-negative tumours [14,15], although many have reported recurrences to be more frequent in HER2-positive tumours compared to ER-positive/HER2-negative tumours [16,17]. This evidence concerns the gene ERBB2 and neoplasm.